Table 2 Presenting clinical and... | American Society of Hematology

Table 2

Presenting clinical and laboratory data of the 56 PMF cases

	Prefibrotic/early fibrotic (grade 0/1)*	Advanced fibrotic (grade 2/3)*	P†	Low/intermediate-1 risk‡	Intermediate-2/high risk‡	P†
Sex, no. (%)
Male	9 (29)	14 (56)		14 (30.4)	9 (90)
Female	22 (71)	11 (44)		32 (69.6)	1 (10)
Age (y) at diagnosis*	63 (25-86)	65 (44-86)	.86	62 (25-88)	71 (57-79)	.1
Hb, g/L	131.6 (92-172)	111 (80-164)	.0003	127.7 (87-172)	98 (80-127)	.0004
WBC, × 10⁹/L	9.6 (3.8-15)	11.9 (2.8-51.5)	.67	10.3 (3.8-22.1)	12.1 (2.8-51.5)	.2
PLT, × 10⁹/L	662.7 (200-1218)	401 (49-1031)	.004	605 (121-1218)	304 (490-753)	.01
Cellularity, %	60.8 (20-90)	71.6 (30-100)	.02	62.9 (20-100)	78 (50-90)	.008
SPARC⁺ stromal cells × HPF	3.9 (0.5-15.9)	6.7 (2.4-15.7)	.0003	4.7 (0.5-15.9)	7.3 (1.4-15.7)	.004
CD146⁺ stromal cells × HPF	6 (1-12.2)	10.2 (3.8-23.5)	.0004	7.5 (1-23.5)	9.3 (3-21)	.4
MVD × HPF	5.8 (1-12.2)	9.9 (2.8-18.6)	.00001	6.5 (1.6-18.6)	8.5 (3-14.8)	.1

	Prefibrotic/early fibrotic (grade 0/1)*	Advanced fibrotic (grade 2/3)*	P†	Low/intermediate-1 risk‡	Intermediate-2/high risk‡	P†
Sex, no. (%)
Male	9 (29)	14 (56)		14 (30.4)	9 (90)
Female	22 (71)	11 (44)		32 (69.6)	1 (10)
Age (y) at diagnosis*	63 (25-86)	65 (44-86)	.86	62 (25-88)	71 (57-79)	.1
Hb, g/L	131.6 (92-172)	111 (80-164)	.0003	127.7 (87-172)	98 (80-127)	.0004
WBC, × 10⁹/L	9.6 (3.8-15)	11.9 (2.8-51.5)	.67	10.3 (3.8-22.1)	12.1 (2.8-51.5)	.2
PLT, × 10⁹/L	662.7 (200-1218)	401 (49-1031)	.004	605 (121-1218)	304 (490-753)	.01
Cellularity, %	60.8 (20-90)	71.6 (30-100)	.02	62.9 (20-100)	78 (50-90)	.008
SPARC⁺ stromal cells × HPF	3.9 (0.5-15.9)	6.7 (2.4-15.7)	.0003	4.7 (0.5-15.9)	7.3 (1.4-15.7)	.004
CD146⁺ stromal cells × HPF	6 (1-12.2)	10.2 (3.8-23.5)	.0004	7.5 (1-23.5)	9.3 (3-21)	.4
MVD × HPF	5.8 (1-12.2)	9.9 (2.8-18.6)	.00001	6.5 (1.6-18.6)	8.5 (3-14.8)	.1

Values are mean (range). HPF (×400).

Fibrosis was evaluated according to Thiele et al.⁷

According to Mann-Whitney U test.

According to Cervantes et al.³¹